Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity

BACKGROUND: The quality of life of patients at all stages of hematological malignancy is greatly affected by the disease and its treatment. There is a wide range of health-related quality of life (HRQoL) issues important to these patients. Any new instrument developed to measure HRQoL of such patien...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Salek, Sam
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066982/
https://ncbi.nlm.nih.gov/pubmed/32210809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00209
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars